Aduro Biotech (Aduro), a Triton launched company formed in 2010, stays at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination; that make transformative advances in the treatment of challenging diseases.
FRX Polymers, Inc.
FRX Polymers, Inc., a (formed by Triton in 2007) manufactures Nofia® polyphosphonates - fire resistant plastics. Nofia products are fully transparent, high flowing and, due to their high phosphorus content, are inherently flame retardant.
Fluence specializes in developing energy-efficient wastewater treatment solutions. The company’s innovative Membrane Aerated Biofilm Reactor (MABR) technology is installed at sites around the world.
Sensera is an integrated, fast turnaround client-specific designer and manufacturer of specialized high performance microsensors and micro-fabricated components for the Healthcare, Industrial, Defense and Aerospace markets.
Featured Incubated Products
A Plug and Play ‘Sensitivity Amplifier’ that enables chemical sensors for threat and contraband detection.
MEMS Sensors & Manufacturing
Sensera designs, engineers and manufactures MEMS-based sensors and other devices for industrial, medical and defense applications.
(Fiber Reinforced Aluminum)
Triton FRA Composites is a fiber reinforced aluminum composite that offers light weight and high strength alternatives to heavy steel for bearing applications.
Triton Systems Company Video
Triton video showcasing it's accomplishments, technologists and the vision of the company for the next generation of innovation. To view: https://www.youtube.com/watch?v=rOETFI7EJ3k
Market and Patent Analyses of Wearables in Medicine
May 1, 2019: Insightful article co-authored by Triton’s Dr. Baris Unal on how wearable medical devices (WMDs) will advance point-of-care diagnostics and therapeutics. This article analyses the market and patents for wearable devices.
Fluence to Establish China Assembly Plant with Annual Capacity of 120 Aspiral™ Units to Meet Expected Future Demand
Melbourne, New York, 27 August 2019: Fluence Corporation Limited (ASX: FLC) is pleased to announce that it has signed a Letter of Intent with the Yiyang High-tech Industrial District Management Committee (“Yiyang High-tech”) for the establishment of a final assembly facility for its proprietary membrane aerated biofilm reactor (“MABR”) products.
Aduro Biotech Present Results from Phase 1b Study of MIW815 in Combination PDR001 in Patients with Advanced Solid Tumors or Lymphomas
BERKELEY, Calif., June 02, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), today announced the presentation of data from an ongoing Phase 1b clinical trial in collaboration with Novartis. Aduro’s ADU-S100 (MIW815), a novel STING pathway activator, is being evaluated in combination with Novartis’ spartalizumab (PDR001), an investigational anti-PD-1 monoclonal antibody, in patients with advanced solid tumors or lymphomas.